Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Acquired by Summit Creek Advisors LLC

Summit Creek Advisors LLC lifted its holdings in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 11.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,612 shares of the biopharmaceutical company’s stock after purchasing an additional 1,099 shares during the quarter. Summit Creek Advisors LLC’s holdings in Horizon Therapeutics Public were worth $1,116,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of HZNP. Janney Montgomery Scott LLC grew its holdings in shares of Horizon Therapeutics Public by 65.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 4,449 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 1,765 shares during the period. Commonwealth Equity Services LLC grew its holdings in shares of Horizon Therapeutics Public by 22.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 36,162 shares of the biopharmaceutical company’s stock worth $3,896,000 after purchasing an additional 6,549 shares during the period. Yousif Capital Management LLC purchased a new position in shares of Horizon Therapeutics Public during the 4th quarter worth $354,000. Robeco Institutional Asset Management B.V. grew its holdings in shares of Horizon Therapeutics Public by 55.9% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 34,528 shares of the biopharmaceutical company’s stock worth $3,721,000 after purchasing an additional 12,381 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Horizon Therapeutics Public during the 4th quarter worth $28,216,000. 88.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on HZNP. UBS Group cut Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and lowered their target price for the company from $137.00 to $71.00 in a report on Thursday. BMO Capital Markets lowered their target price on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a report on Thursday. Wells Fargo & Company restated a “buy” rating and set a $133.00 target price on shares of Horizon Therapeutics Public in a report on Friday, April 8th. The Goldman Sachs Group lowered their target price on Horizon Therapeutics Public from $164.00 to $144.00 and set a “buy” rating for the company in a report on Thursday. Finally, SVB Leerink cut Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Horizon Therapeutics Public has an average rating of “Moderate Buy” and an average target price of $117.22.

Insider Transactions at Horizon Therapeutics Public

In other news, CEO Timothy P. Walbert sold 17,600 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total transaction of $1,584,000.00. Following the sale, the chief executive officer now owns 460,549 shares of the company’s stock, valued at approximately $41,449,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Timothy P. Walbert sold 17,600 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total transaction of $1,584,000.00. Following the sale, the chief executive officer now owns 460,549 shares of the company’s stock, valued at approximately $41,449,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andy Pasternak sold 762 shares of Horizon Therapeutics Public stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $85.36, for a total value of $65,044.32. Following the transaction, the executive vice president now directly owns 38,897 shares in the company, valued at approximately $3,320,247.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,384 shares of company stock valued at $8,934,633. Corporate insiders own 2.50% of the company’s stock.

Horizon Therapeutics Public Stock Performance

Shares of HZNP opened at $69.60 on Friday. The stock has a 50-day simple moving average of $83.03 and a 200-day simple moving average of $93.34. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.30 and a current ratio of 4.05. The stock has a market capitalization of $16.03 billion, a PE ratio of 21.48, a PEG ratio of 1.13 and a beta of 1.12. Horizon Therapeutics Public Limited has a 1 year low of $60.76 and a 1 year high of $120.54.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.29). Horizon Therapeutics Public had a return on equity of 27.90% and a net margin of 20.06%. The business had revenue of $876.40 million for the quarter, compared to analyst estimates of $938.82 million. During the same period last year, the business posted $1.62 EPS. Horizon Therapeutics Public’s revenue was up 5.3% on a year-over-year basis. On average, analysts predict that Horizon Therapeutics Public Limited will post 5.68 earnings per share for the current fiscal year.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.